Synonyms: ABT-874 | J-695 | J695 | Ozespa
Compound class:
Antibody
Comment: Briakinumab is a recombinant, fully human, IgG1 investigational monoclonal antibody targeting the shared p40 subunit of IL-12 and IL-23. Peptide sequences matching those of briakinumab are claimed in patent US6914128 'Human antibodies that bind human IL-12 and methods for producing' [2].
![]() View more information in the IUPHAR Pharmacology Education Project: pericyazine |
Classification ![]() |
|
Compound class | Antibody |
International Nonproprietary Names ![]() |
|
INN number | INN |
9153 | briakinumab |
Synonyms ![]() |
ABT-874 | J-695 | J695 | Ozespa |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 162 |
Other databases | |
GtoPdb PubChem SID | 315661289 |
Search PubMed clinical trials | briakinumab |
Search PubMed titles | briakinumab |
Search PubMed titles/abstracts | briakinumab |